Recent Stories
American Biotech — The Future Can’t Be Won Without It.RSI is AI Building AI. What DC needs to know about it. Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: Robots

The Wave

Senatein sessionHousein session
Refreshed just now
News

STAT+: Most-favored nations policy makes drugmakers rethink launches abroad

Why it’s here: The item is a newsletter-style roundup bundling several stories, but its lead concerns Trump's most-favored-nations drug pricing policy and its effect on launch decisions, which is a biotech federal policy issue.

Trace across the board

Item

Connected

1 links

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy

STAT+: Most-favored nations policy makes drugmakers rethink launches abroad — The Wave